NeuroPace Becomes Exclusive U.S. Distributor of DIXI’s Product Line

NeuroPace Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, has entered into a commercialization agreement with DIXI Medical USA, under which NeuroPace will become the exclusive U.S. distributor of DIXI’s product line effective October 1, 2022.
 
Under the terms of the agreement, NeuroPace will have exclusive rights to promote and sell stereoelectroencephalography (SEEG) electrodes in the U.S.
 
SEEG electrodes are used in the epilepsy monitoring units of comprehensive epilepsy centers to determine where epileptic seizures originate. Physicians use this information to target interventional treatments at the seizure source, including with the NeuroPace RNS System.
 
DIXI will continue to support U.S. physicians as well as education and outreach activities to inform patients and HCPs of the treatment options available for drug refractory epilepsy. For these support services, DIXI will receive an upfront payment along with two additional payments in 2023 and 2024.
 
“Epilepsy centers in the U.S. are increasingly using SEEG as a minimally invasive approach to determine appropriate treatment options for epilepsy patients, including through the use of the RNS System,” said Mike Favet, CEO of NeuroPace. “This synergistic partnership leverages the existing NeuroPace field organization, which is already calling on the same customers, and supports our objective to engage earlier in the diagnostic and therapy selection process.”
 
“As SEEG becomes more and more popular among U.S. epileptologists and neurosurgeons, we needed to extend our reach. We are pleased to entrust DIXI electrodes in the U.S. to the strong and competent team at NeuroPace. The untapped potential of interventional treatments for epilepsy is so large that it deserves combining the energy and creativity of our companies,” commented Frederic Koehn, president of DIXI Medical. “As a specialty provider in this market for more than 40 years, DIXI shares a commitment with NeuroPace to deliver innovative solutions for healthcare providers to better manage epilepsy care.”